$2.5m Contract for clinical self-test development
Abingdon Health plc has secured a significant contract valued at approximately US$2.5 million for the development and regulatory submission of a clinical self-test, with the majority of revenue expected in the financial year ending June 30, 2027. This 18-month project will involve Abingdon Health providing end-to-end project management and technical support across feasibility, design, development, verification, and validation phases, leveraging their expertise in lateral flow test development and regulatory pathways. The contract reinforces Abingdon Health's position as a leading provider of integrated CDMO/CRO services in the rapid diagnostic test market.
Select text to share a quote on X · sign in to keep highlights & notes in your ABDX notes
York, U.K. 12 March 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it has been awarded a significant contract with an expected value of approximately US$2.5 million to provide project management and expert technical support for the development and regulatory submission of a clinical self-test.
The Company has signed a Services Agreement with this UK-based customer to be delivered in phases over an 18-month period via orders under the Services Agreement. The project represents a strategically important contract in the clinical self-test diagnostics sector and demonstrates Abingdon Health's expertise in managing complex, multi-stakeholder international diagnostic programmes. The contract will commence shortly with the majority of the revenues to be recognised in the financial year ending 30 June 2027.
Abingdon Health will provide end-to-end project management and technical support across three key phases: Feasibility, Design & Development and Verification & Validation. The work leverages the Company's established capabilities in lateral flow test development, clinical diagnostics, ISO 13485:2016 quality management systems, and regulatory pathways.
This contract award underscores Abingdon Health's position as a leading provider of integrated CDMO/CRO services for rapid diagnostic tests.
Dr Chris Hand, Executive Chairman, commented: "We are delighted to have been selected and to be working with this client on this important global health project. Our multidisciplinary in-house immunodiagnostics specialists, regulatory experts, and programme managers are ideally suited to deliver this complex international programme. This award reinforces our strategic position in the point-of-contact diagnostics market and demonstrates the value of our CDMO/CRO platform to major international organisations."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.